Trial Profile
Open-Label, Multicenter, Phase II Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Jan 2024
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Docetaxel (Primary) ; Nimotuzumab (Primary)
- Indications Carcinoma; Nasopharyngeal cancer
- Focus Therapeutic Use
- 16 Jan 2024 Planned End Date changed from 30 Dec 2026 to 30 Jun 2024.
- 16 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 02 Apr 2019 Status changed from not yet recruiting to recruiting.